Browse Articles
Discover research articles across all indexed journals
Intravesical gemcitabine and docetaxel combined with intravenous tislelizumab as a durable strategy for high-risk non–muscle-invasive bladder cancer.
703 Background: For decades, intravesical Bacillus Calmette-Guérin (BCG) has been the standard treatment for high-risk non-muscle-invasive bladder cancer (HR NMIBC). However, its poor tolerability and limited availability underscore the urgent need for more effective therapies. Intravesical sequential gemcitabine and docetaxel (GemDoce) has demonstrated efficacy in HR NMIBC, and immune checkpoint inhibitors (ICIs) have shown effectiveness as second-line therapy for patients with BCG-unresponsive NMIBC. Nevertheless, the combination of immunotherapy with intravesical GemDoce has not yet been reported. Methods: We retrospectively analyzed HR NMIBC patients, who received intravesical GemDoce combined with intravenous tislelizumab at Fujian Medical University Union Hospital from February 2023 to August 2024. Induction GemDoce was administered weekly for 6 weeks, then monthly maintenance. Tislelizumab started during the second GemDoce treatment and continued every 4 weeks. Inclusion required at least 6 weekly GemDoce after complete transurethral resection of bladder tumor (TURBT). Data including patient clinicopathologic features, treatment history, adverse events (AEs), and oncologic outcomes were retrospectively reviewed and analyzed. Results: 30 patients included in study, with a median number of 16 (range:6-22) GemDoce treatments and 12 (range:2-18) tislelizumab cycles. Median age was 70 (range:49-80) years. All patients had papillary disease with or without CIS, including 11 (36.7%) with HGTa and 19 (63.3%) with HGT1. CIS with HGTa was present in 2 (6.7%) patients. 5 (16.7%) patients were BCG-naïve HR NMIBC, while 25 (83.3%) patients were recurrent HR NMIBC. Most patients were male (90%, 27/30), and 56.7% (17/30) had a smoking history. Treatment was well tolerated with no discontinuations or dose reductions. In total, 12 (40%) patients reported AEs following treatment, all of which were grade 1-2. Median follow-up of 11.5 (range:2-18) months, no patients had recurrence, underwent RC, or died. Conclusions: These results suggest that intravesical GemDoce with intravenous tislelizumab is an effective and tolerable treatment option for patients with HR NMIBC. Further prospective study is warranted.
RAD-SG: Adaptive radiation therapy with concurrent sacituzumab govitecan (SG) for bladder preservation in patients (pts) with muscle invasive bladder cancer (MIBC).
TPS896 Background: Concurrent chemoradiotherapy (CRT) is a recommended treatment option for pts with MIBC interested in bladder-preservation and/or not candidates for radical cystectomy (RC). Systemic radio-sensitizing chemotherapy may have off target side effects and exploring novel agents with radiation is an unmet need. SG is an antibody drug conjugate (ADC) and has shown efficacy in metastatic urothelial cancer (UC). RAD-SG is a single-arm phase 1 trial investigating the concurrent administration of SG with adaptive radiotherapy (RT) in pts with MIBC. Methods: Eligibility criteria include pts with localized MIBC (T2-T4aN0M0), ECOG PS Score of 0-2, normal organ and marrow function including creatinine clearance ≥ 30 mL/min, must undergo a TURBT within ≤ 60 days prior to treatment. Variant subtypes are allowed. Pts must not have had UC or any histological variant at any site outside of bladder within 24 months except Ta/T1/Carcinoma in situ (CIS) of the upper urinary tract including renal, pelvis, and ureter if underwent complete nephroureterectomy. Other exclusion criteria include bilateral hydronephrosis and prior pelvic / local RT for MIBC or any other cancer type. SG targets TROP-2, a surface protein expressed in UC, it will be given IV at 7.5 mg/kg every 21days starting prior to RT and 2 subsequent cycles with concurrent adaptive RT over a period of 6 weeks (64 Gy). The primary endpoint is safety, tolerability, and feasibility of trimodality therapy with concurrent SG and adaptive image-guided radiation therapy for patients with localized MIBC. The secondary endpoints are bladder intact event-free survival (BI-EFS) with concurrent SG and RT for MIBC and compare historical controls with other concurrent CRT regimens. BI-EFS is defined as the time from treatment to the first documented occurrence of residual/recurrent MIBC, nodal or distant metastases on imaging, RC, or death from any cause. Correlative objectives include 1) elucidation of the genetic and microenvironmental mechanisms that drive efficacy and resistance to combined ADC plus RT and 2) characterization of tumor clonal dynamics, immune repertoire editing, and imaging changes following treatment with SG plus RT. The study will accrue 20 pts at Cleveland Clinic Foundation and enrollment is ongoing. (NCT05833867). Clinical trial information: NCT05833867 .
Global potential of sustainable single-cell protein based on variable renewable electricity
Abstract The environmental impacts of the food system exceed several planetary boundaries, with protein production being a major contributor. Single-Cell Protein (SCP) is a protein-rich microbial biomass that offers a sustainable alternative when derived from renewable energy and sustainable feedstocks. We evaluate the global potential for SCP production utilising electrolytic hydrogen and oxygen, atmospheric carbon dioxide and nitrogen, and hourly-optimised hybrid PV-wind power plants at a 0.45° × 0.45° spatial resolution. We outline a roadmap for industrial-scale production, commencing in 2028, targeting an annual capacity of 30 million tonnes of protein by 2050. Here we show that the cost of renewable electricity-based protein (e-protein) could decline at optimal sites from 5.5–6.1 € kg−1 in 2028 to 4.0–4.5 € kg−1 by 2030, and further to 2.1–2.3 € kg−1 by 2050. Consequently, e-protein production can mostly decouple protein supply from water and arable land constraints, substantially mitigating the environmental impacts of food production.
Exploration of phosphoproteomic association during epimorphic regeneration
Individualized neoantigen vaccine with nivolumab plus cabozantinib for translocation renal cell carcinoma: Single patient investigational new drug.
537 Background: Translocation renal cell carcinoma (tRCC) is a rare renal cell carcinoma subtype found in about 1-4% of adult patients with RCC and 40% of pediatric RCC cases. Management of advanced tRCC has been guided by clear cell RCC therapy and retrospective reviews which include tRCC cohorts. Novel therapeutic strategies are needed to improve outcomes. This study assessed an individualized neoantigen vaccine with nivolumab plus cabozantinib in a patient with metastatic TFE3-tRCC. Methods: Patient was consented (IRB# 20-011945) for a single-patient investigational new drug (IND#27755). In-house neoantigen prediction bioinformatics pipeline (REAL-neo v2.0) was performed to identify and prioritize neoantigen candidates. Patient underwent lymphodepletion with cyclophosphamide followed by vaccine administration on days 1, 4, 8, 11, 20, 40, week 12, and week 20. Patient was also treated with concurrent nivolumab 480 mg every 4 weeks and cabozantinib 40 mg daily. Objective response rate (ORR) and progression-free survival (PFS) were measured. Results: Patient was diagnosed with TFE3-tRCC and underwent nephrectomy prior to developing metastatic disease. He was treated with multiple liver surgeries, ablations, and radiation therapy without systemic therapy. This controlled his disease for 7 years before he required systemic therapy with ipilimumab plus nivolumab. After 4 cycles, imaging showed progression and was started on cabozantinib which controlled his disease for 1 year. Patient was consented for the neoantigen vaccine. Cycle 1 was administered in April 2022. Three liver lesions and 1 periportal lymph node were monitored. After 4 months of therapy, imaging showed partial response with 34% decrease in sum of target lesions. In June 2023, partial response was ongoing with a 57.4% decrease. A 2 nd vaccine series was administered in June 2023 and had stable disease until progression in June 2024 when patient held his cabozantinib for at least 4 weeks. Neoantigen combination therapy achieved a progression-free survival of 26 months and was well tolerated without significant vaccine-related adverse events. Conclusions: Individualized neoantigen vaccine plus nivolumab and cabozantinib achieved a durable partial response with prolonged progression-free survival. A randomized clinical trial is warranted to further evaluate the efficacy of this combination therapy.
Impact of adding immunotherapy to chemotherapy for metastatic neuroendocrine bladder cancer in the National Cancer Database.
748 Background: Metastatic neuroendocrine bladder cancer is a rare and aggressive malignancy characterized by poor prognosis and limited effective treatment options. Standard chemotherapy has shown limited success, necessitating novel therapies. We hypothesized that adding immunotherapy to chemotherapy would improve overall survival (OS) in these patients. Methods: We conducted a retrospective cohort study of 1,410 patients diagnosed with metastatic neuroendocrine bladder cancer between 2004 and 2020 using the National Cancer Database (NCDB). Treatment groups included no treatment, chemotherapy alone, and combined immunochemotherapy. Survival outcomes were analyzed using Kaplan-Meier curves, log-rank tests, and Cox proportional hazards regression models, adjusting for age, tumor size, Charlson-Deyo comorbidity score, and residential area. Results: Median OS was 1.8 months (95% CI: 1.6-2.0) for patients receiving no treatment (n=460), 9.6 months (95% CI: 8.9-10.1) for chemotherapy alone (n=860), and 11.7 months (95% CI: 9.6-14.8) for combined immunochemotherapy (n=90) (P < 0.001 for immunochemotherapy vs. both other groups). Further analysis revealed that first-line immunotherapy initiated within 30 days of chemotherapy (n=21) significantly improved OS (median 11.6 months; 95% CI: 6.8–16.1; P=0.0374) compared to chemotherapy alone. Notably, immunotherapy initiated after 30 days (n=69, median OS 12.4 months; 95% CI: 9.0–14.8; P=0.0264), whether as first-line or second-line therapy, also showed superior efficacy to chemotherapy alone. These findings suggest that if first-line immunotherapy is not administered, subsequent immunotherapy should still be considered. Multivariable Cox regression analysis showed that immunochemotherapy compared to chemotherapy alone was associated with a lower hazard for death (HR = 0.80; 95% CI: 0.66-0.97; P = 0.0242), while patients receiving no treatment had an increased risk of death (HR = 3.50; 95% CI: 3.00-3.90; P < 0.0001). Additional factors associated with increased mortality included older age, larger tumor size, and higher Charlson-Deyo score. Conclusions: Adding immunotherapy to chemotherapy significantly improved OS in metastatic neuroendocrine bladder cancer. First-line immunochemotherapy showed substantial benefits, but late initiation also improved outcomes. These findings support incorporating immunotherapy into first-line protocols and consider it for subsequent lines. Prospective clinical trials are needed to optimize immunotherapeutic strategies for this aggressive malignancy.
Determining an immunohistochemical profile to predict response to intravesical bacillus Calmette–Guérin (BCG) in patients with high-grade non-muscle invasive bladder cancer.
847 Background: Intravesical Bacillus Calmette–Guérin (BCG) remains the gold standard for the management of high-grade non-muscle invasive bladder cancer (NMIBC). However, up to 70% of patients fail BCG therapy. We aimed to define potential mechanisms for BCG resistance and develop an immunohistochemical (IHC) panel to help identify patients likely to respond to intravesical BCG. Methods: Patients with NMIBC undergoing induction intravesical BCG at a tertiary institution were identified. Twelve BCG-responders and 13 non-responders were matched for patient and tumour factors. RNA sequencing was performed with hierarchical clustering and Gene Set Enrichment Analysis to identify response resistance mechanisms. Immune cell subsets were measured using pre and post-BCG therapy for CD4, CD8, T-Bet, GATA-3 and PD-1 antibodies. GATA-3 and T-Bet stains were used as surrogates for Th-2 and Th-1 cells, respectively. T-tests were used to assess differences. An integrated IHC panel using CD4, CD8, T-Bet, GATA and PD1 was developed and correlated with BCG response using Receiver Operator Characteristic (ROC) curves. Results: On hierarchical clustering, BCG-responders and non-responders had distinct gene expression profiles pre- and post-BCG. Prior to exposure to BCG, non-responders had enrichment for a pro-inflammatory gene signature with a higher CD4:CD8 ratio (2.94 vs 1.71, p=0.0003) and a higher Th-2/Th-1 (GATA/T-Bet) ratio (5.95 vs 2.97, p=0.0026) compared to BCG-responders, on IHC. However, on exposure to BCG, non-responders had no changes to the CD4:CD8 or Th-2/Th-1 ratios but had a 78% increase in the PD-1 expression (MD 20.83/5hpf, p=0.016) with BCG, indicating T cell exhaustion. In contrast, upon exposure to BCG, responders had an increase in the Th-2/Th-1 ratio (mean difference 0.9323, p=0.0228) with enrichment of the natural killer cell pathway compared to non-responders (p<0.05). The area under the ROC curve using the integrated IHC panel to predict BCG response was 0.864 (95% CI: 0.663 to 1.000). Conclusions: BCG non-responders had a pro-inflammatory TME, which showed marked T cell exhaustion on exposure to BCG. In contrast, responders had a baseline TME with low CD4:CD8 and low Th-2/Th-1 ratios at baseline, which allowed activation of both humoral and adaptive responses to BCG. These immune changes can be utilised as an IHC panel to predict response to BCG therapy.
Evaluating the impact of single vs. combination therapy on survival outcomes in mHSPC patients stratified by BMI.
187 Background: Metastatic hormone sensitive prostate cancer (mHSPC) is a heterogenous disease with a variety of treatment options. De novo mHSPC can be treated with androgen deprivation therapy (ADT) monotherapy or combinations including docetaxel or androgen receptor pathway inhibitors. Body mass index (BMI) is known to be associated with survival, but there is little data to show the effectiveness of treatment intensity (single or combination therapy) based on BMI. Methods: Patients treated for mHSPC within the Veterans Health Affairs from 2017-2023 were included. BMI was assessed using height and weight at diagnosis and treatment intensity was determined by treatments within 4 months of start of ADT. Additional baseline characteristics for each group included age, prostate specific antigen (PSA), and Charlson Comorbidity Index (CCI). Survival was estimated using the Kaplan-Meier method and Cox proportion hazard modeling was used to account for known covariates. Results: There were 4184 veterans identified with 33.5% BMI <25, 35% BMI 25-30, and 31.5% with BMI >30. The BMI 25-30 group had longer survival compared to BMI of <25 (37.3 vs. 30.7 months, HR 0.78 95% CI 0.71-0.86) and the BMI >30 had longer survival compared to BMI 25-30 (42.5 vs. 37.3 months, HR 0.87 95% CI 0.79-0.96). In patients with BMI of <25 combination therapy was associated with longer survival (HR 0.73 (0.63-0.83)) and in patients with BMI of 25-30, combination therapy was also associated with longer survival 0.76 (0.67-0.88). However, in patients with BMI >30, there was no difference in overall survival based on combination or monotherapy (HR 0.97 (0.83-1.13)). In a multivariable model including age, PSA, CCI, and treatment intensity, BMI >30 and BMI 25-30 was associated with decreased risk of death compared to BMI <25, aHR 0.80 (95% CI 0.72-0.89) and aHR 0.89 (95% CI 0.81-0.98) respectively. Conclusions: In patients with mHSPC, higher BMI is associated with longer survival compared to lower BMI. In all patients, combination therapy was associated with longer survival, however, there was no difference in survival with combination therapy compared to monotherapy in patients with BMI >30. Future studies could investigate the reason why combination therapy is only associated with benefit in patients with BMI <30. BMI (kg/m 2 ) <25 n=1403 25-30 n=1465 >30 n=1316 P value (ANOVA) Age (mean years) 76.2 74.4 71.8 p<0.001 PSA (median ng/mL) 177 91.6 61.25 p<0.001 Overall Survival (median months) 30.7 37.3 42.5 p<0.001 ADT monotherapy 26.9 (n=736) 33.1 (n=683) 42.5 (n=582) Combination therapy 36.3 (n=667) 41.5 (n=782) 42.6 (n=734) HR (95% CI) 0.73 (0.63-0.83) 0.76 (0.67-0.88) 0.97 (0.83-1.13)
Structural, molecular and developmental evidence for cell-type diversity in cnidarian mechanosensory neurons
Experimental study on adiabatic pre-cooling systems for air cooled condensers in hot and humid climates
Clinical outcomes of invasive primary urethral cancer: A real world multi-institutional study.
654 Background: Primary urethral cancer (PUC) is a rare and highly aggressive malignancy with a spectrum of various histologies without an established treatment approach. Due to the lack of prospective studies in patients with PUC, the clinical outcomes with different treatment modalities are unknown. We aimed to investigate the clinical outcomes based on various treatment approaches and histology. Methods: Our retrospective study included patients from 10 international cancer centers in the United States, Europe, and Asia. Eligibility criteria included patients diagnosed with invasive PUC based on the TNM stage (T2-T4, N0-N2). We defined disease free survival (DFS) as time from date of cancer diagnosis to recurrence or death, whichever came first. We utilized Kaplan-Meier survival analysis to study the DFS rate. Results: We identified 82 patients diagnosed with PUC, of which 60% were men and 40% were women. The common histologies were urothelial carcinoma (40%), squamous carcinoma (32%), adenocarcinoma (12%). Patients had stage II (30%), III disease (26%) and IV disease (44%). In this cohort 51% underwent surgery only (S), 19% received neoadjuvant chemotherapy f/w surgery (NCT), 11% received concurrent chemoradiation f/w by surgery (CRT), 2% received radiation f/w surgery. In our cohort 43% patients had recurrence of disease. In our study cohort, the DFS rate was 54 % after a median follow up of 15.5 months. The 2-year DFS rates were 64.2% for urothelial carcinoma, 45.7% for adenocarcinoma, and 40.0% for squamous cell carcinoma. Based on treatment, 2-year DFS rates were 68% for NCT, 58.3% for CRT, and 46% for S respectively. Median DFS rate was 41 months in patients with lymph node metastasis (LMN) vs 30 months in patients without LMN. Among 14 patients who underwent genomic testing, the most common gene alterations were seen in PIK3CA (35%), PTEN (21%), ERBB-2 (14%) and CDKN2A/B (28%). Conclusions: The management of PUC is complex given the variable histologies. Clinical outcomes appear suboptimal with high rates of recurrence in patients with invasive PUC regardless of histology, treatment, and sex. While our study is limited by its retrospective design, sample size and limited follow up, data suggest that multimodal therapy incorporating chemotherapy with or without radiation may offer better outcomes in invasive PUC. Future large scale prospective studies are needed to optimize treatment approaches in patients with PUC. 2-year DFS based on histology, treatment approach and stage. Survival rate (%) [95%CI] DFS (Histology) Urothelial 64 [43 - 79] Adenocarcinoma 45 [14 - 72] Squamous 40 [17 - 61] DFS (Treatment) S 46 [29 - 62] NCT 68 [35 - 86] CRT 58 [18 - 84] DFS (Gender) Male 51 [34 - 66] Female 51 [31 - 67] DFS (AJCC stage) II 62 [39 - 79] III 50 [29 - 70] IV 50 [25 - 67]
Phase III randomized trial of stereotactic ablative radiotherapy (SAbR) for oligometastatic advanced renal carcinoma (EA8211-SOAR).
TPS615 Background: The optimal frontline management strategy for oligometastatic renal cell carcinoma (omRCC) is uncertain. Systemic therapy (ST) is the standard, but Stereotactic Ablative Radiation (SAbR) offers an alternative, and may potentially reduce ST-associated toxicity. However, concerns remain about occult micro-metastases progression with SAbR. Retrospective studies suggest focal therapies may improve outcomes in select patients, but prospective data is limited. This ECOG-ACRIN phase 3 randomized trial compares SAbR with ST in omRCC, assessing whether SAbR followed by delayed ST can offer non-inferior OS with lower toxicity compared to upfront ST. The co-primary endpoints are OS and grade ≥3 toxicity. Hypothesis: For omRCC patients with 2-5 measurable metastases, SAbR followed by delayed ST will result in non-inferior OS compared to immediate while reducing grade ≥3 toxicity. Methods: This phase 3 trial will enroll patients with oligometastatic RCC with 2-5 extracranial metastases amenable to SAbR and an ECOG performance status of 0-2, categorized as favorable or intermediate risk according to modified IMDC criteria. Patients must have their primary tumor treated by surgery or radiation before enrollment. Exclusions include brain metastases, sarcomatoid histology, prior systemic therapy for metastatic disease (adjuvant therapy is allowed), and poor-risk IMDC classification. Participants will be stratified by number of metastases, histology, IMDC risk, prior adjuvant therapy, and time since primary site treatment. Patients will be randomized to either upfront ST or SAbR with delayed ST. Statistical Design: The trial has 85% power to establish non-inferiority of SAbR with respect to OS, assuming a null hazard ratio of 1.24 and an alternative of 0.85. If non-inferior OS is shown, the study will test whether SAbR reduces grade ≥3 toxicity. Secondary endpoints include progression-free survival (PFS) and quality of life, measured by NFKSI-19 and EQ-5D-5L scales. Exploratory endpoints will assess cost-effectiveness and circulating tumor DNA (ctDNA) as a biomarker. The study opened in September 2023. Research sponsor: U.S. National Institutes of Health. Clinical trial information: NCT05863351 .
A prospective trial of a structured exercise program to lessen fatigue in patients with advanced prostate cancer (aPC) undergoing androgen deprivation therapy (ADT).
120 Background: Cancer-related fatigue, one of the most significant issues affecting quality of life (QOL), is reported by up to 75% of men with advanced prostate cancer (aPC) on ADT. Exercise may serve as a tool to improve fatigue in cancer patients. We examined the effect of a structured exercise program on fatigue in men with aPC. Methods: This prospective trial enrolled participants with aPC treated with an ADT-based regimen on a 12 week exercise program at a single institution. Patients with at least 4/10 tiredness, self-reported sedentary lifestyle (<90 min/week exercise), no evidence of disease progression, and no chemotherapy within 3 months were eligible. Participants underwent peak aerobic capacity, muscular strength and endurance testing before and after 12 weeks of structured, guided exercise through the institution’s hospital-based exercise oncology program called Personal Optimism With Exercise Recovery (POWER). Participants completed symptom questionnaires including the 7-item PROMIS fatigue at baseline and after 6 and 12 weeks. Participants had 45-60 min supervised sessions weekly, either in person or virtually, and were instructed to work up to 150 min of moderate activity and 2 resistance training sessions weekly. The primary endpoint was change in fatigue; a 4 point reduction in T score is a clinically important difference. The key secondary endpoint was change in relative peak aerobic capacity (ml/kg/min). Mean and 95% Gaussian confidence intervals are reported. Results: 119 participants with aPC, 92% of whom had metastatic disease, enrolled between 2018 and 2022. Nine withdrew from the study and 10 were lost to follow-up. Data were incomplete for 28 participants primarily due to inadequate follow-up during COVID. Of the 119 enrolled participants, 96% were white, 83% were married, 52% had at least a college degree, and 25% were currently employed. Mean age was 70.3 years and mean BMI was 30.5 kg/m 2 . 29 participants (24%) were receiving treatment with ADT alone, and the rest were receiving a combination of ADT and targeted therapy. The primary endpoint was evaluable in 72 participants. There was a clinically significant reduction in fatigue of 5.1 points (95%CI 3.6-6.7) between baseline (56.7 [95%CI 55.1-58.0]) and 12 weeks (51.4 [95%CI 49.8-53.1]). Of those who completed both aerobic fitness assessments (n=76), there was a 3.1 ml/kg/min (95%CI 2.1-4.0) improvement in relative peak aerobic capacity from a mean 27.5 [95%CI 25.8-29.2] at baseline to a mean 30.6 [95%CI 28.8-32.3] at 12 weeks. Conclusions: Completion of a 12 week supervised exercise regimen led to a clinically significant improvement in fatigue and peak aerobic exercise capacity. These findings support routinely recommending exercise for and examining symptom management in patients with metastatic cancer to improve QOL. Clinical trial information: NCT03421782 .
World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis from the X-MET collaboration.
15 Background: Metastasis-directed therapy (MDT) for omPC has demonstrated progression-free survival (PFS) benefit in multiple phase 2 randomized clinical trials (RCTs) yet has fallen short of demonstrating benefit for later endpoints. The X-MET collaboration amalgamates IPD from RCTs investigating oligometastatic cancers, incorporating new trials when published. Within X-MET, WOLVERINE combined IPD from all published omPC MDT RCTs. Methods: Trial search identified 5 omPC RCTs of MDT and standard of care (SOC) vs. SOC alone: STOMP (NCT01558427), ORIOLE (NCT02680587), ARTO (NCT03449719), SABR-COMET (NCT01446744), and EXTEND (continuous and intermittent androgen deprivation therapy [ADT] baskets; NCT03599765). IPD were retrieved for all trials. PFS was defined as biochemical or radiographic (RECIST 1.1) progression or death. Castration-resistance free survival (CRFS) was analyzed in castration-sensitive prostate cancer (CSPC) patients and was defined as development of castration-resistant prostate cancer (CRPC) or death. Meta-analyses were conducted using fixed- and random-effects models to calculate pooled hazard ratios (HRs). As a complementary approach, HRs were computed utilizing Cox regression stratified by trial. The analysis plan was archived in Prospero: CRD4203479078. Results: This analysis included 472 patients, 224 randomized to SOC and 248 randomized to MDT+SOC, with a median follow-up of 41 mo. The majority were CSPC (58%), treated with ADT (74%) +/- androgen receptor pathway inhibitors (ARPI; 54%), and had a previously treated primary prostate (82%). For both analyses, MDT significantly improved PFS, radiographic PFS (rPFS), and CRFS (Table). Meta-analysis utilizing fixed- and random-effects yielded similar results. Overall survival (OS) was excellent in both arms (3- and 4-year OS: MDT+SOC 92% and 87% vs. SOC 86% and 75%) and exhibited near-significant association with MDT. The benefit of MDT for PFS persisted across most subgroups including castration status, prior primary treatment, staging imaging, and ADT/ARPI use (all HR < 0.52, all P < 0.05, all P[interaction] > 0.05). Conclusions: Leveraging IPD from all published omPC RCTs, WOLVERINE demonstrated for the first time a significant benefit of MDT for longer term endpoints including rPFS and CRFS, in addition to a near-significant association with OS. Furthermore, MDT benefit persisted across the entire omPC disease spectrum ranging from de novo to metachronous and CSPC to CRPC. Association between MDT and outcomes. Cox regression: HR (95% CI) Random-effects model: HR (95% CI) PFS 0.45 (0.35-0.58), P<0.0001 0.44 (0.35-0.57), P<0.0001 rPFS 0.59 (0.46-0.76), P<0.0001 0.60 (0.43-0.85), P=0.0039 CRFS 0.58 (0.37-0.91), P=0.020 0.58 (0.37-0.92), P=0.019 OS 0.64 (0.40-1.01), P=0.057 0.63 (0.39-1.004), P=0.051
A neuronal code for object representation and memory in the human amygdala and hippocampus
Abstract How the brain encodes, recognizes, and memorizes general visual objects is a fundamental question in neuroscience. Here, we investigated the neural processes underlying visual object perception and memory by recording from 3173 single neurons in the human amygdala and hippocampus across four experiments. We employed both passive-viewing and recognition memory tasks involving a diverse range of naturalistic object stimuli. Our findings reveal a region-based feature code for general objects, where neurons exhibit receptive fields in the high-level visual feature space. This code can be validated by independent new stimuli and replicated across all experiments, including fixation-based analyses with large natural scenes. This region code explains the long-standing visual category selectivity, preferentially enhances memory of encoded stimuli, predicts memory performance, encodes image memorability, and exhibits intricate interplay with memory contexts. Together, region-based feature coding provides an important mechanism for visual object processing in the human brain.
Self-supervision advances morphological profiling by unlocking powerful image representations
Characterization, treatment and survival outcomes of penile cancer: Over a decade in a tertiary Mexican center.
5 Background: Penile cancer, as a rare disease worldwide, represents 4.1% of urological cancers in Mexico. Despite the need for multimodal treatments, delayed diagnoses and poor follow-up adherence impact survival outcomes. This study aims to characterize the patient population diagnosed with penile cancer at a tertiary center in Mexico and evaluate treatment and survival outcomes. Methods: This cross-sectional retrospective cohort study analyzed patients diagnosed with penile cancer at the medical oncology and urology services of Centro Médico Nacional 20 de Noviembre from January 2005 to January 2024. Statistical analyses included Kaplan-Meier survival analysis and subgroup analyses by age, surgical treatment type and radiotherapy. Results: Of the 54 patients analyzed, the median age was 64 years (34-84) with a median time symptoms to diagnosis of 12 months. Clinical stages at diagnosis were stage I (9.2%), II (40.7%), III (29.6%) and IV (20.3%). Human papillomavirus (HPV) was positive in 17 patients (31.4%), negative in 2 (3.7%) and undetermined in 35 (64.8%). HIV status was undetermined in 88.8% of cases. Additionally, 22 patients (40.7%) were smokers. Tumor anatomical locations were glans (64.8%), prepuce (25.9%), body of the penis (7.4%) and scrotum (1.8%). Histologically, all cases were squamous cell carcinoma. Most common sites of metastasis were lymph nodes (79.6%), lungs (7.4%) and liver (5.5%). Systemic therapy was administered to 38.8% and radiotherapy to 55.5% with a median overall survival of 44.8 months. Surgical treatment was required in most cases (88.8%), with total penectomy and bilateral inguinal dissection predominating in 21 patients (38.9%), followed by total penectomy alone in 8 (14.8%), partial penectomy with bilateral inguinal dissection in 6 (11.1%) and partial penectomy in 8 (14.8%). Tumor resection alone was performed in 5 (9%). Subgroup analysis based on age, surgical technique and radiotherapy indicated that overall survival was not significantly affected by age when comparing patients <60 years to those >60 years (p=0.1). However, patients undergoing partial penectomy had significantly higher survival rates (12 months vs 7 months; p=0.04), regardless of clinical stage. There was no significant difference in overall survival between patients who received radiotherapy and those who did not (p=0.7). Conclusions: Despite advanced stage at diagnosis, the results suggest that surgical intervention is associated with improved survival rates. However, neither age nor radiotherapy significantly impacted overall survival outcomes, likely due to the homogeneity of clinical stages and surgical approaches. These findings underscore the importance of early detection and comprehensive management strategies to improve survival in this patients.
Prostate Cancer Supportive Care (PCSC) program: An alternative to consolidated framework for implementation research (CFIR) model.
346 Background: The CFIR model is one approach to implementing supportive care services. It requires extensive resources, staff training, and reliance on infrastructure. In contrast, the PCSC Program grew organically based on knowledge of patient-expressed needs. Rather than tailoring services to individuals, the PCSC Program offers a menu of services that the patient can choose from with the help of a program coordinator. Methods: We compared the implementation considerations for CFIR (1) to those of the PCSC Program. Results: Patient Needs Assessment & Staffing: CFIR assesses needs at diagnosis using specific tools in the EHR and recommends a care plan formulated by a multidisciplinary team. In contrast, PCSC empowers patients to self-select services from eight modules (see table below) based on their needs after registration, whether at diagnosis or beyond. This flexibility allows the program to operate efficiently, freeing up clinician time for delivering group education sessions and clinic appointments. Resource Management and follow-up: CFIR identifies community resources with a multidisciplinary team. This may require referrals and clinic-specific communication. This approach may lead to inconsistencies and variation in patient experience. In contrast, PCSC provides all services at a single site that is familiar to many patients as it is across from the urology clinic. Clinic visits are in person or virtual, allowing access to all patients across the province. This model eliminates the need for extensive documentation, and the quality of the services is controlled centrally. Since there is transparency on available services from the outset, patients may return as needed, negating the need for individualized formal follow-up assessments. Sustainability and Impact: While CFIR is process-driven, PCSC’s model has supported over 5,288 patients and their families, free of charge, with $3.25 million in philanthropic support over 11 years in addition to grants and government funding, underscoring the community's trust in the program's efficacy and value. Conclusions: CFIR is a structured and resource-intensive approach that focuses on the individual patient. The PCSC Program presents patients with a menu of services known to be of importance to this population and offers a flexible, patient-driven approach. The longevity of the PCSC Program and the patient satisfaction responses suggest that this is an alternative model for delivering supportive care. 1. Stout et al JCO Oncol Pract 20:1173-1181. Attendance for 5288 registrants from 2013 to 09/2024. Modules Attendees 2013-9/2024, n Introduction to PC and Primary Treatment Options 1994 Managing Sexual Function and Intimacy 2461 Management of side effects of ADT 809 Pelvic Floor Physiotherapy for Incontinence 1890 Counselling 852 Metastatic Disease Management 162 Nutrition 1527 Exercise 1336
Implementation and preliminary validity of the Functional Assessment of Cancer Therapy – Radionuclide Therapy (FACT-RNT) in patients receiving radionuclide therapy for prostate cancer.
118 Background: The Functional Assessment of Cancer Therapy-Radionuclide Therapy (FACT-RNT) is used in trials and clinical practice to monitor patient-reported RNT-relevant symptoms and toxicities in advanced metastatic castrate-resistant prostate cancer (mCRPC) patients receiving RNT. This study examined FACT-RNT feasibility and preliminary validity for U.S. patients receiving RNT. Methods: Patients scheduled to start 177Lu-PSMA-617 for advanced mCRPC at Moffitt Cancer Center from October 2023 – March 2024 completed patient-reported outcome (PRO) measures before each cycle. PROs included previously validated measures of prostate cancer specific-symptoms (NFPSI-17) and physical function (Scored Patient-Generated Subjective Global Assessment; PG-SGA) and the FACT-RNT, a 15-item measure of symptoms/toxicities with higher total scores (range: 0-60) indicating less symptom burden. Correlations between the FACT-RNT and other PROs were calculated. Results: Patients (N=17) were, on average, 69 years old (SD=11, range=43-90) at RNT cycle 1 and mostly non-Hispanic (76%) and White (82%). Gleason scores at diagnosis were 7-8 (30%) or 9-10 (71%). Patients had previously undergone surgery (35%), chemotherapy (94%), radiation (71%), hormone therapy (94%), targeted therapy (88%), and immunotherapy (29%). Fifteen patients (88%) received ≥2 RNT infusions; of these, 1 (6%) died and 1 (6%) discontinued RNT prior to cycle 2. Thirteen (87% of those with ≥2 infusions) completed the FACT-RNT at ≥2 cycles. Cycle 1 FACT-RNT total scores ranged from 31-58 (M=46.5, SD=8). The FACT-RNT was positively associated with symptoms as assessed by NFPSI-17 at cycles 1-3 ( p s≤.03) and negatively associated with physical function at cycles 1-2 ( p s≤.05). Conclusions: Preliminary results support FACT-RNT validity due to associations with validated PRO measures and the feasibility of FACT-RNT implementation in the U.S. The FACT-RNT may be helpful in clinical management and decision-making with RNT recipients. Future research will replicate and extend these findings in a larger longitudinal sample and examine validity with clinician-rated outcomes and RNT dosimetry.
Comparative survival outcomes of non-clear cell and clear cell renal cell carcinomas with indications for adjuvant pembrolizumab.
515 Background: While immunotherapy has become first-line treatment for metastatic renal cell carcinoma in both clear cell (ccRCC) and non-clear cell (nccRCC) histologies, there has been limited investigation into adjuvant therapies for nccRCC in the context of high-risk localized RCC. As adjuvant Pembrolizumab is being more commonly employed for high-risk non-metastatic ccRCC, its application in nccRCC remains less understood. This study aims to compare survival outcomes between patients with high-risk localized ccRCC and nccRCC, focusing on cancer-specific survival (CSS) and overall survival (OS). Methods: Prospectively collected data from a multicenter database, including University of California San Diego Health (USA), IRCCS San Raffaele Hospital (Italy), Emory University Hospital (USA) and Tokyo Medical and Dental University (Japan), were retrospectively analyzed. Non-metastatic patients treated with surgery were included. The cohort was divided between nccRCC and ccRCC groups for descriptive and survival analyses, with the aim of comparing survival of the two groups according to subgrouping factors, specifically high-grade disease (G3-G4 or sarcomatoid features) at final pathology (HG) and locally advanced disease (pathological stage T3). Kaplan-Meier analyses (KMA) and Cox regression multivariable analyses (COX) were conducted to evaluate for cancer-specific survival (CSS) and overall survival (OS) and predictors of cancer-specific (CSM) and all-cause mortality (ACM). Results: With median follow-up of 58 months, a total of 5968 patients were analyzed. 4724 (79%) patients had a ccRCC while 1244 (21%) had a nccRCC. The nccRCC cohort comprised 923 (74%) papillary, 240 (19%) chromophobe and 81 (7%) variant histology patients. KMA comparing nccRCC high-grade (G3-G4; HG) tumors and ccRCC high-grade (HG) tumors showed no difference in 5-year CSS rates (nccRCC-HG 91% vs ccRCC-HG 88%, p=0.08) and 5-year OS (nccRCC-HG 79% vs ccRCC-HG, p=0.1). Comparing T3 stage tumors between nccRCC and ccRCC, KMA also showed similar 5-year CSS (nccRCC-T3 83% vs. ccRCC-T3 84%, p=0.05) and 5-year OS (nccRCC-T3 73% vs ccRCC-T3 73%, p=0.2). Cox regression for predictors of mortality showed that histology was not an independent predictor of CSM (p=0.17) and ACM (p=0.11). Conclusions: Although focus of most RCC adjuvant therapy clinical trials has been on ccRCC, aggressive features in nccRCC patients yield similar 5-year cancer-specific and overall survival rates. This study highlights the need for further clinical trials to evaluate efficacy of adjuvant systemic therapy in the setting of unfavorable groups of non-clear cell RCC.